Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 10/28 07:40:15 pm
115 USD   -0.61%
06:41p JOHNSON & JOHNS : Does baby powder cause cancer? Another jury says y..
12:21p JOHNSON & JOHNS : Woman wins £58m after claiming Johnson's baby powd..
09:21a JOHNSON & JOHNS : St. Louis jury awards $70 million to woman claimin..
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : J&J Cancer Drug Zytiga Now Backed For Publicly Funded Use In UK

share with twitter share with LinkedIn share with facebook
share via e-mail
05/16/2012 | 11:11am CEST

The U.K.'s health-care cost-effectiveness regulator Wednesday reversed an earlier decision and approved the publicly funded use of Johnson & Johnson's (JNJ) prostate-cancer pill Zytiga, after the U.S. company cut its price further.

Also known as abiraterone, Zytiga removes the prostate cancer tumor's supply of testosterone, preventing it from growing further and potentially extending a patient's life by more than three months. The medicine was rejected for use in the U.K. in February on grounds its terms of use wouldn't offer value for money.

Andrew Dillon, chief executive of the U.K.'s National Institute for Health and Clinical Excellence, or NICE, Wednesday said the manufacturer subsequently submitted fresh information, including a revised patient access scheme containing a deeper price discount to the National Health Service and more information about which patients would most benefit from its use and how many patients could receive the drug.

"These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS," Dillon said in a statement. "It is an effective treatment, potentially extending life by more than three months, and it also allows patients to be treated at home as it can be taken orally."

Abiraterone costs GBP2,930 for a 30-day supply of 120 tablets. NICE didn't specify the size of the price cut offered by Johnson & Johnson.

Zytiga was approved by U.S. and European drug regulators last year. It is set to generate peak-year sales of $910 million.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
06:41p JOHNSON & JOHNSON : Does baby powder cause cancer? Another jury says yes.
04:22p JOHNSON & JOHNSON : Health Workers, Others Exposed to Cervical Cancer Prevention
12:21p JOHNSON & JOHNSON : Woman wins £58m after claiming Johnson's baby powder gave he..
09:21a JOHNSON & JOHNSON : St. Louis jury awards $70 million to woman claiming baby pow..
06:11a JOHNSON & JOHNSON : Jury awards more than $70M to woman in baby powder lawsuit
10/27 Johnson & Johnson Reports 2016 Third-Quarter Results
10/27 Verb Surgical Inc. Honored by Goldman Sachs for Entrepreneurship - Scott Huen..
10/27 JOHNSON & JOHNSON : Jules Musing, Former Senior Executive at Johnson & Johnson, ..
10/27 JOHNSON & JOHNSON : Pinnacle Advisory Group buys $1,202,448 stake in Johnson & J..
10/27 JOHNSON & JOHNSON (NYSE : JNJ) Faces Competition From Mylan Concerta Knockoff
More news
Sector news : Pharmaceuticals - NEC
07:06pDJEU Opens In-Depth Probe Into ChemChina's Bid for Syngenta
06:34p FTSE edges higher as IAG boosts travel stocks
03:56pDJABBVIE : Sales of AbbVie's Humira Miss Expectations
03:47pDJABBVIE : Revenue and Profit Rise, but Humira Misses Expectations
03:36pDJU.S. HOT STOCKS : Hot Stocks to Watch
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08:00a GLAXOSMITHKLINE : Has Q3 2016 Seen The Positive Momentum Continue Building?
10/27 Should You Buy Pfizer Now?
10/26 INSIDERINSIGHTS.COM DAILY ROUND UP 1 : Cree, mcc, reed, erc
10/26 GLOBAL BLOOD THERAPEUTICS : Incredible Value At This Price
10/26 Create Your Own Johnson & Johnson Dividend
Financials ($)
Sales 2016 72 080 M
EBIT 2016 21 940 M
Net income 2016 16 371 M
Finance 2016 19 430 M
Yield 2016 2,71%
P/E ratio 2016 19,58
P/E ratio 2017 17,26
EV / Sales 2016 4,12x
EV / Sales 2017 3,84x
Capitalization 316 541 M
More Financials
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 126 $
Spread / Average Target 9,2%
Consensus details
EPS Revisions
More Estimates Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON12.64%316 541
ROCHE HOLDING LTD.-18.05%200 403
PFIZER INC.0.62%197 012
NOVARTIS AG-17.97%188 860
MERCK & CO., INC.16.04%169 480
SANOFI-12.39%96 780
More Results